Capmatinib side effects and contraindications

Clinical studies of Capmatinib, a targeted therapy for certain types of cancer, have revealed a range of common side effects. The most frequent adverse reactions in patients treated with this drug were edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough, and decreased appetite. The incidence rate of these adverse reactions exceeds 20%, and patients and medical staff need to pay close attention.

In addition to the common adverse reactions mentioned above, capmatinib may also trigger some warnings and precautions. The risk of interstitial lung disease (ILD) or pneumonia needs to be taken seriously, especially in patients with a history of respiratory disease. In addition, the use of capmatinib is also associated with the risk of hepatotoxicity, and patients should regularly monitor liver function during treatment to ensure timely detection of potential problems. These serious reactions may affect the patient's quality of life or even be life-threatening, so special caution should be used when using this drug.

Another aspect of note is pancreatic toxicity, which may cause patients to experience symptoms such as abdominal pain, nausea, and vomiting. Early recognition and management of these symptoms is critical to reduce the impact on the patient's overall health. In addition, there are side effects such as allergic reactions and photosensitivity risks that require patients to be vigilant, especially when taking protective measures during outdoor activities.

For pregnant and lactating women, capmatinib's embryonic-fetal toxicity reminds patients to avoid pregnancy during use and to use appropriate contraceptive measures according to the doctor's advice after treatment. Overall, the use of capmatinib should be carried out under the guidance of professional medical personnel to ensure that patients can weigh the benefits and potential risks of treatment on an informed basis.